These success, along with a former report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like actions in mice,2 assist the thought of concentrating on ACKR3 as a unique approach to modulate the opioid program, which could open new therapeutic avenues for opioid-relev